RxDoctor Payments DataLook up a doctor →

Arshad Khanani, MD

Ophthalmology · Reno, NVNPI 1295929511

Payments from drug & device makers

$45,834,530in general payments, 2019–2025

Across 3,888 payments — averaging $11,789 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$27.2M
  • Ocular Therapeutix, Inc.$7.5M
  • Novartis$3.9M
  • Roche TCRC, Inc.$2.2M
  • Kyowa Kirin, Inc.$1.2M
  • Eyepoint US, Inc.$848K
  • plus $2.9M from 44 others
$160,360in research payments, 2019–2025

Across 98 payments — averaging $1636.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$99K
  • Novartis$37K
  • Novartis Pharma AG$14K
  • Ocular Therapeutix, Inc.$10K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.1,502$27,242,251
Ocular Therapeutix, Inc.508$7,547,103
Novartis164$3,867,385
Roche TCRC, Inc.174$2,224,311
Kyowa Kirin, Inc.336$1,169,272
Eyepoint US, Inc.23$848,004
Janssen Research & Development, LLC120$489,435
AbbVie(2 entities)237$368,967
Astellas Pharma Global Development52$310,865
Sanofi US Services Inc.31$301,245
AstraZeneca3$295,021
F. Hoffmann-la Roche AG78$274,913
Genentech USA, Inc.258$220,683
Astellas Pharma US Inc87$203,435
Novartis Pharma AG31$148,316
Apellis Pharmaceuticals, Inc.61$127,038
Thrombogenics, Inc.19$34,907
Roche Products Limited6$34,367
Alcon24$27,584
Regeneron15$21,466
Amgen(2 entities)5$13,665
Regeneron Healthcare Solutions, Inc.16$10,504
Bausch & Lomb Americas Inc.28$9,475
Dutch Ophthalmic, USA4$7,142
Janssen Global Services, LLC8$6,523
ANI Pharmaceuticals, Inc.5$4,236
Boehringer Ingelheim International GmbH12$4,144
Biogen11$3,025
Dutch Ophthalmic Research Center (international) B.v.1$3,000
Bausch & Lomb, A Division Of Bausch Health US, LLC19$2,542
Sun Pharmaceutical Industries Inc.2$2,335
Samsung Bioepis Co., Ltd.2$2,200
Harrow Eye, LLC8$1,839
Glaukos Corporation1$1,800
Alcon Research LLC2$1,700
Neurotech Pharmaceuticals, Inc.4$1,589
Alimera Sciences, Inc.10$1,544
Oyster Point Pharma, Inc.3$194
Hoffmann-la Roche Limited1$99
Sanofi-aventis U.S. LLC1$89
Biotissue Holdings Inc.4$79
Johnson & Johnson Surgical Vision, Inc.3$56
Kala Pharmaceuticals, Inc.2$35
Optos, Inc.1$26
Astellas Pharma Inc1$24
Thea Pharma Inc.1$23
Vyera Pharmaceuticals, LLC1$21
Carl Zeiss Meditec AG1$19
Notal Vision, Inc.1$18
Coherus Oncology, Inc.1$16

How this compares

$45,834,530 in reported general payments places this provider in the 95th percentile of 121 ophthalmology providers in Nevada.

See all ophthalmology providers in Nevada →

Medicare billing

Part B allowed, 2024
$9,953,055
Medicare patients
1,508
Services billed
234,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Reno

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →